Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.40 |
| ▸ | FLT1 | P17948 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 5/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25793120 | 1.00 | KDR (0.40) | KDRFLT1MAPK14CYP17A1FGFR4 | |
| SCHEMBL25245433 | 0.91 | MAPK14 (0.39) | KDRFLT1MAPK14FGFR4RET | |
| SCHEMBL29958957 | 0.89 | MAPK14 (0.36) | KDRFLT1MAPK14FGFR4RET | |
| SCHEMBL25793116 | 0.89 | KDR (0.43) | KDRFLT1MAPK14CYP17A1RET | |
| SCHEMBL29959168 | 0.89 | KDR (0.43) | KDRFLT1MAPK14CYP17A1RET | |
| SCHEMBL25793117 | 0.89 | KDR (0.44) | KDRFLT1MAPK14CYP17A1RET | |
| SCHEMBL30486148 | 0.89 | CYP17A1 (0.36) | KDRFLT1MAPK14CYP17A1BRAF | |
| SCHEMBL30486130 | 0.88 | KDR (0.42) | KDRFLT1MAPK14CYP17A1RET | |
| SCHEMBL25793118 | 0.88 | KDR (0.42) | KDRFLT1MAPK14CYP17A1RET | |
| SCHEMBL25793115 | 0.83 | KDR (0.43) | KDRFLT1CYP17A1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177382-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-20240400551-A1 | NEK7 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | KDR 4751/4885FLT1 4178/4885MAPK14 717/4885 |
| US-20250177382-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | KDR 4717/4885FLT1 4274/4885MAPK14 944/4885 |
| US-20240400551-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | KDR 4456/4885FLT1 3937/4885MAPK14 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.